B
셀레스트라
352770KOSDAQ의료용품 및 기타 의약 관련제품 제조업58.5 / 100
Reference Date: 2026-07-24
Financial Score26.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Celestera develops and commercializes services for early disease diagnosis using genome-based biohealth information processing, liquid biopsy platforms, cancer diagnostics, and multi-omics technologies. Key products include Geno-Test, CD-Prime, and Cancer-Prime, with a dedicated bio big data center for research and commercialization.
Number of Employees
11people
Average Salary
85.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.184.0Point
PBR
—Industry Average 1.093.5Point
ROE
3157.50Industry Average -4.893.5Point
Well below industry avg
Debt Ratio
-10.65Industry Average 6.868.0Point
Half of industry avg (excellent)
Trend 2023~20257.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼50.9% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲45.0% (2-year basis)
ROE Trend
4.0 / 4
Avg ROE 951.3% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position4.0Point
52w mid range (50%)
Current 5,250Won52-week high 5,25052-week low 5,250
1-month return3.0Point
1m 0% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0